Alignment Healthcare (NASDAQ:ALHC) Cut to Hold at Zacks Research

Zacks Research downgraded shares of Alignment Healthcare (NASDAQ:ALHC) from a strong-buy rating to a hold rating in a report released on Tuesday,Zacks.com reports.

Several other analysts also recently weighed in on ALHC. Wall Street Zen downgraded Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Sunday, August 10th. Barclays raised shares of Alignment Healthcare from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $9.00 to $13.00 in a report on Thursday, July 31st. KeyCorp raised Alignment Healthcare from a “sector weight” rating to an “overweight” rating and set a $21.00 price objective on the stock in a report on Monday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, October 8th. Finally, The Goldman Sachs Group started coverage on Alignment Healthcare in a research note on Tuesday, October 14th. They set a “buy” rating and a $21.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.05.

Alignment Healthcare Trading Down 6.0%

ALHC opened at $17.12 on Tuesday. The company has a 50-day simple moving average of $16.86 and a 200 day simple moving average of $15.55. Alignment Healthcare has a twelve month low of $10.18 and a twelve month high of $21.06. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 2.29. The stock has a market capitalization of $3.39 billion, a price-to-earnings ratio of -61.14 and a beta of 1.18.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. Alignment Healthcare had a negative net margin of 1.53% and a negative return on equity of 43.68%. The company had revenue of $993.70 million during the quarter, compared to the consensus estimate of $980.90 million. During the same quarter in the prior year, the firm posted ($0.14) EPS. The firm’s quarterly revenue was up 43.5% on a year-over-year basis. Alignment Healthcare has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts predict that Alignment Healthcare will post -0.69 EPS for the current fiscal year.

Insider Transactions at Alignment Healthcare

In other Alignment Healthcare news, Director Atlantic (Aln Hlth) L. General sold 6,246,096 shares of the business’s stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $16.01, for a total value of $99,999,996.96. Following the transaction, the director directly owned 24,596,079 shares of the company’s stock, valued at approximately $393,783,224.79. The trade was a 20.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher J. Joyce sold 30,939 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $16.41, for a total value of $507,708.99. Following the completion of the transaction, the insider directly owned 343,592 shares in the company, valued at approximately $5,638,344.72. This trade represents a 8.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 7,427,716 shares of company stock valued at $119,650,069. 7.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Alignment Healthcare

Several institutional investors have recently made changes to their positions in ALHC. Vanguard Group Inc. raised its stake in Alignment Healthcare by 13.2% during the 1st quarter. Vanguard Group Inc. now owns 11,113,896 shares of the company’s stock worth $206,941,000 after buying an additional 1,295,825 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in Alignment Healthcare by 5.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 9,078,113 shares of the company’s stock worth $169,035,000 after buying an additional 429,071 shares during the period. Wellington Management Group LLP raised its stake in Alignment Healthcare by 0.9% during the 1st quarter. Wellington Management Group LLP now owns 7,509,057 shares of the company’s stock worth $139,819,000 after buying an additional 70,557 shares during the period. Hood River Capital Management LLC raised its position in shares of Alignment Healthcare by 6.0% during the second quarter. Hood River Capital Management LLC now owns 5,517,336 shares of the company’s stock worth $77,243,000 after purchasing an additional 311,424 shares during the period. Finally, 8 Knots Management LLC raised its position in shares of Alignment Healthcare by 6.4% during the second quarter. 8 Knots Management LLC now owns 5,015,881 shares of the company’s stock worth $70,222,000 after purchasing an additional 300,409 shares during the period. Institutional investors and hedge funds own 86.19% of the company’s stock.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.